Researcher finds Baxdelta2 tumor suppressor can be generated in some colon cancer cells

June 12, 2014

(Medical Xpress)—Illinois Institute of Technology researcher Jialing Xiang, who recently discovered Baxdelta2, the powerful tumor suppressor found only in mutated cells, has learned more about its cell death-causing mechanism and therapeutic implications.

Certain colon tumors with genetic microsatellite instability often lose Bax due to microsatellite mutation. But a Bax alternative isoform, Baxdelta2, can be "salvaged" from the mutated gene. Xiang has found that Baxdelta2-positive cells are selectively sensitive to chemotherapeutics through an unconventional signaling pathway. This means that colorectal tumors thought to have been "Bax-negative" may instead be able to generate the Baxdelta2 that will be beneficial for chemotherapeutic treatment.

Xiang and her team reported their findings in the journal Molecular Cancer Research. Their work is supported by the National Cancer Institute (NCI) in the National Institutes of Health (NIH).

The pro-apoptotic (cell death-causing) protein Bax is one of the universal tumor suppressors in our body. Loss of Bax will have a negative effect on the cellular "suicide" program and promote development. The ability to generate Baxdelta2 means the cancer cell might be triggered to re-start the apoptotic (cell death-causing) process.

"Discovery of Baxdelta2 will lead us to a better understanding of the 'Bax-negative' colon cancer and potentially provide targeted chemotherapeutics for treatment," said Xiang.

One of the areas that Xiang's team is working on is to find out how the production of Baxdelta2 is controlled and to identify drugs that can enhance Baxdelta2 production in .

Explore further: Immune cell death defects linked to autoimmune diseases

More information: "Baxdelta2 Promotes Apoptosis through Caspase-8 Activation in Microsatellite Unstable Colon Cancer." Honghong Zhang, Yuting Lin, Adriana Manas, Yu Zhao, Mitchell F. Denning, Li Ma, and Jialing Xiang. Mol Cancer Res molcanres.0162.2014; Published OnlineFirst May 19, 2014; DOI: 10.1158/1541-7786.MCR-14-0162

Related Stories

Immune cell death defects linked to autoimmune diseases

January 23, 2013
Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune ...

New study shows promise for preventing therapy resistance in tumor cells

January 9, 2014
A new study led by University of Kentucky researchers suggests that activating the tumor suppressor p53 in normal cells causes them to secrete Par-4, another potent tumor suppressor protein that induces cell death in cancer ...

Newly identified brain cancer mutation will aid drug development

June 1, 2014
A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.